Amgen, Inc. (AMGN) is Candriam Luxembourg S.C.A.’s 6th Largest Position

Candriam Luxembourg S.C.A. cut its position in Amgen, Inc. (NASDAQ:AMGN) by 21.7% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 463,575 shares of the medical research company’s stock after selling 128,168 shares during the period. Amgen comprises 1.5% of Candriam Luxembourg S.C.A.’s portfolio, making the stock its 6th largest holding. Candriam Luxembourg S.C.A.’s holdings in Amgen were worth $86,434,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the company. Janus Henderson Group PLC boosted its position in shares of Amgen by 3,664.7% during the second quarter. Janus Henderson Group PLC now owns 3,699,351 shares of the medical research company’s stock worth $637,139,000 after acquiring an additional 3,601,087 shares during the last quarter. FMR LLC boosted its position in shares of Amgen by 4.8% during the second quarter. FMR LLC now owns 56,999,572 shares of the medical research company’s stock worth $9,817,037,000 after acquiring an additional 2,587,041 shares during the last quarter. Renaissance Technologies LLC boosted its position in shares of Amgen by 40.9% during the second quarter. Renaissance Technologies LLC now owns 3,400,145 shares of the medical research company’s stock worth $585,607,000 after acquiring an additional 986,700 shares during the last quarter. BlackRock Inc. boosted its position in shares of Amgen by 1.9% during the second quarter. BlackRock Inc. now owns 49,451,203 shares of the medical research company’s stock worth $8,516,980,000 after acquiring an additional 909,689 shares during the last quarter. Finally, Nordea Investment Management AB boosted its position in shares of Amgen by 12.9% during the second quarter. Nordea Investment Management AB now owns 7,040,599 shares of the medical research company’s stock worth $1,212,602,000 after acquiring an additional 806,119 shares during the last quarter. 78.46% of the stock is owned by hedge funds and other institutional investors.

A number of equities analysts recently weighed in on the stock. Oppenheimer set a $205.00 target price on shares of Amgen and gave the stock a “buy” rating in a research report on Friday, January 5th. Vetr lowered shares of Amgen from a “buy” rating to a “hold” rating and set a $184.25 target price for the company. in a research report on Wednesday, January 3rd. Piper Jaffray Companies restated a “buy” rating on shares of Amgen in a research report on Tuesday, January 2nd. Mizuho set a $192.00 target price on shares of Amgen and gave the stock a “buy” rating in a research report on Thursday, December 28th. Finally, Citigroup lowered shares of Amgen to a “neutral” rating in a research report on Monday, December 18th. One analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and ten have issued a buy rating to the company. The company currently has an average rating of “Hold” and an average price target of $190.15.

In related news, Director Carbonnel Francois De sold 4,000 shares of the firm’s stock in a transaction dated Wednesday, November 8th. The shares were sold at an average price of $173.61, for a total value of $694,440.00. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, EVP Sean E. Harper sold 1,525 shares of the firm’s stock in a transaction dated Tuesday, December 12th. The stock was sold at an average price of $176.83, for a total transaction of $269,665.75. Following the completion of the transaction, the executive vice president now directly owns 56,106 shares in the company, valued at approximately $9,921,223.98. The disclosure for this sale can be found here. Insiders sold a total of 7,050 shares of company stock worth $1,225,765 in the last ninety days. 0.19% of the stock is currently owned by insiders.

Shares of Amgen, Inc. (NASDAQ AMGN) opened at $182.86 on Thursday. The stock has a market cap of $132,740.00, a PE ratio of 16.52, a PEG ratio of 2.60 and a beta of 1.36. The company has a quick ratio of 5.72, a current ratio of 6.07 and a debt-to-equity ratio of 1.05. Amgen, Inc. has a twelve month low of $150.38 and a twelve month high of $191.10.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings results on Wednesday, October 25th. The medical research company reported $3.27 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $3.11 by $0.16. The company had revenue of $5.77 billion for the quarter, compared to the consensus estimate of $5.75 billion. Amgen had a net margin of 35.54% and a return on equity of 29.90%. The firm’s revenue was down .7% compared to the same quarter last year. During the same quarter last year, the firm posted $3.02 EPS. research analysts expect that Amgen, Inc. will post 12.71 earnings per share for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Thursday, March 8th. Investors of record on Thursday, February 15th will be paid a $1.32 dividend. This represents a $5.28 annualized dividend and a yield of 2.89%. The ex-dividend date of this dividend is Wednesday, February 14th. This is an increase from Amgen’s previous quarterly dividend of $1.15. Amgen’s dividend payout ratio (DPR) is currently 41.55%.

Amgen declared that its board has approved a stock buyback program on Wednesday, October 25th that authorizes the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization authorizes the medical research company to reacquire shares of its stock through open market purchases. Shares repurchase programs are often a sign that the company’s board of directors believes its stock is undervalued.

ILLEGAL ACTIVITY WARNING: “Amgen, Inc. (AMGN) is Candriam Luxembourg S.C.A.’s 6th Largest Position” was first published by Community Financial News and is the sole property of of Community Financial News. If you are viewing this report on another site, it was stolen and reposted in violation of United States and international trademark and copyright law. The legal version of this report can be viewed at https://www.com-unik.info/2018/01/11/amgen-inc-amgn-is-candriam-luxembourg-s-c-a-s-6th-largest-position.html.

About Amgen

Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

What are top analysts saying about Amgen? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Amgen and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit